Further Understanding of the Immune Microenvironment in Head and Neck Squamous Cell Carcinoma: Implications for Prognosis

The right Timing, right combination, right sequence, and right delivery for Cancer immunotherapy

(2021) Minsu Kwon et al.   JOURNAL OF CONTROLLED RELEASE

Identification of a Prognostic Immune Signature for Esophageal Squamous Cell Carcinoma to Predict Survival and Inflammatory Landscapes

(2021) Chaoqi Zhang et al.   Frontiers in Cell and Developmental Biology

Radiotherapy, immunotherapy, and the tumour microenvironment: Turning an immunosuppressive milieu into a therapeutic opportunity

(2021) N.E. Donlon et al.   CANCER LETTERS

Immune-related gene signature for predicting the prognosis of head and neck squamous cell carcinoma

(2020) Yangyang She et al.   Cancer Cell International

Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer

(2020) Anthony R. Cillo et al.   IMMUNITY

Cancer associated fibroblasts confer shear resistance to circulating tumor cells during prostate cancer metastatic progression

(2020) Nerymar Ortiz-Otero et al.   Oncotarget

The Immune Microenvironment in Head and Neck Squamous Cell Carcinoma: on Subsets and Subsites

(2020) Niels E. Wondergem et al.   Current Oncology Reports

Tumor Microenvironment and Immunotherapy Response in Head and Neck Cancer

(2020) Panagiota Economopoulou et al.   Cancers

Characteristics of the Tumor Microenvironment That Influence Immune Cell Functions: Hypoxia, Oxidative Stress, Metabolic Alterations

(2020) Ryan C. Augustin et al.   Cancers

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

(2019) Brian I Rini et al.   LANCET

Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer

(2019) Athanassios Argiris et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

(2019) Barbara Burtness et al.   LANCET

NER-factor DDB2 regulates HIF1α and hypoxia-response genes in HNSCC

(2019) Prashant V. Bommi et al.   ONCOGENE

Stromal-Immune Score-Based Gene Signature: A Prognosis Stratification Tool in Gastric Cancer

(2019) Hao Wang et al.   Frontiers in Oncology

Identification and Validation of an Immune-Related RNA Signature to Predict Survival of Patients With Head and Neck Squamous Cell Carcinoma

(2019) Shuo Wu et al.   Frontiers in Genetics

Clinical relevance and suppressive capacity of human MDSC subsets

(2018) Stephan Lang et al.   CLINICAL CANCER RESEARCH

Myeloid-derived suppressor cells coming of age

(2018) Filippo Veglia et al.   NATURE IMMUNOLOGY

Targeting Tumor Metabolism: A New Challenge to Improve Immunotherapy

(2018) Soumaya Kouidhi et al.   Frontiers in Immunology

Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck

(2018) Robert L. Ferris et al.   JAMA Oncology

Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response

(2018) Peng Jiang et al.   NATURE MEDICINE

Local angiotensin II contributes to tumor resistance to checkpoint immunotherapy

(2018) Guozhu Xie et al.   Journal for ImmunoTherapy of Cancer

Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy

(2018) Y -P Chen et al.   ANNALS OF ONCOLOGY

Immunometabolic Alterations by HPV Infection: New Dimensions to Head and Neck Cancer Disparity

(2018) Sanjib Chaudhary et al.   JNCI-Journal of the National Cancer Institute

Turning foes to friends: targeting cancer-associated fibroblasts

(2018) Xueman Chen et al.   NATURE REVIEWS DRUG DISCOVERY

MDSC; the Most Important Cell You Have Never Heard Of

(2018) R.J. Tesi   TRENDS IN PHARMACOLOGICAL SCIENCES

Angiotensin 1-7 inhibits angiotensin II-stimulated head and neck cancer progression

(2017) E. E. Hinsley et al.   EUROPEAN JOURNAL OF ORAL SCIENCES

Tumour-associated macrophages as treatment targets in oncology

(2017) Alberto Mantovani et al.   Nature Reviews Clinical Oncology

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

(2017) Zachary R. Chalmers et al.   Genome Medicine

Comprehensive genomic characterization of head and neck squamous cell carcinomas

(2015)   NATURE

PD-1 blockade attenuates immunosuppressive myeloid cells due to inhibition of CD47/SIRPα axis in HPV negative head and neck squamous cell carcinoma

(2015) Guang-Tao Yu et al.   Oncotarget

Much More than M1 and M2 Macrophages, There are also CD169+ and TCR+ Macrophages

(2015) Leslie Chávez-Galán et al.   Frontiers in Immunology

Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma

(2015) Simona Partlová et al.   OncoImmunology

The Role of Antiangiogenic Agents in the Treatment of Head and Neck Cancer

(2012) N. Denaro et al.   ONCOLOGY

Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors

(2011) B. Diop-Frimpong et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Carcinoma-Associated Fibroblast-Like Differentiation of Human Mesenchymal Stem Cells

(2008) P. J. Mishra et al.   CANCER RESEARCH